1. Home
  2. LEGN vs TFII Comparison

LEGN vs TFII Comparison

Compare LEGN & TFII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • TFII
  • Stock Information
  • Founded
  • LEGN 2014
  • TFII 1957
  • Country
  • LEGN United States
  • TFII Canada
  • Employees
  • LEGN N/A
  • TFII 26287
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • TFII Trucking Freight/Courier Services
  • Sector
  • LEGN Health Care
  • TFII Industrials
  • Exchange
  • LEGN Nasdaq
  • TFII Nasdaq
  • Market Cap
  • LEGN 6.7B
  • TFII 7.9B
  • IPO Year
  • LEGN 2020
  • TFII N/A
  • Fundamental
  • Price
  • LEGN $33.11
  • TFII $93.63
  • Analyst Decision
  • LEGN Strong Buy
  • TFII Buy
  • Analyst Count
  • LEGN 12
  • TFII 11
  • Target Price
  • LEGN $73.36
  • TFII $119.27
  • AVG Volume (30 Days)
  • LEGN 1.1M
  • TFII 270.1K
  • Earning Date
  • LEGN 11-11-2025
  • TFII 10-20-2025
  • Dividend Yield
  • LEGN N/A
  • TFII 1.87%
  • EPS Growth
  • LEGN N/A
  • TFII N/A
  • EPS
  • LEGN N/A
  • TFII 4.34
  • Revenue
  • LEGN $796,838,000.00
  • TFII $8,263,477,999.00
  • Revenue This Year
  • LEGN $70.75
  • TFII N/A
  • Revenue Next Year
  • LEGN $52.47
  • TFII $4.03
  • P/E Ratio
  • LEGN N/A
  • TFII $21.55
  • Revenue Growth
  • LEGN 74.75
  • TFII 3.10
  • 52 Week Low
  • LEGN $27.34
  • TFII $72.02
  • 52 Week High
  • LEGN $52.31
  • TFII $155.12
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 36.16
  • TFII 51.72
  • Support Level
  • LEGN $33.20
  • TFII $90.74
  • Resistance Level
  • LEGN $34.71
  • TFII $95.12
  • Average True Range (ATR)
  • LEGN 1.22
  • TFII 2.15
  • MACD
  • LEGN -0.09
  • TFII -0.25
  • Stochastic Oscillator
  • LEGN 10.96
  • TFII 33.33

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About TFII TFI International Inc.

TFI International Inc is involved in the provision of transportation and logistics services across the United States, Canada, and Mexico. The company's reportable segments are; Less-Than-Truckload, which derives maximum revenue, Truckload, and Logistics. The Less-Than-Truckload segment engages in pickup, consolidation, transport, and delivery of smaller loads; the Truckload segment deals with full loads carried directly from the customer to the destination using a closed van or specialized equipment to meet customers' specific needs; and the Logistics segment provides asset-light logistics services, including brokerage, freight forwarding, and transportation management, as well as small package parcel delivery. Geographically, the company generates maximum revenue from the United States.

Share on Social Networks: